COMMUNIQUÉS West-GlobeNewswire

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) [...]
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close [...]
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
22/07/2026
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
22/07/2026
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026
New AMA Category III codes, effective July 1, 2026, support the development of future reimbursement pathways for temporary transvenous diaphragm neurostimulation EXTON, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Lungpacer [...]
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22/07/2026
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin [...]
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, [...]
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
22/07/2026
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and [...]
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
22/07/2026
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Acentra Health Appoints Sreedevi Hegde as Senior Vice President – India Country Head
22/07/2026
Seasoned global business leader to drive the growth of Acentra Health's India organization and accelerate the company's transformation journey MCLEAN, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
22/07/2026
Sales rise 29.3% and EBITDA grows 68.1%; newly appointed Board of Directors to lead the next phase of aerospace and defense growth Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of [...]
ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
22/07/2026
Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio's leadership team as it prepares to advance RBP-01 into the clinic RBP-01 targets primary uveal melanoma, the most [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
22/07/2026
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 Halle (Saale) / Munich, Germany, July 22 , 2026 - Vivoryon [...]
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07/2026
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus [...]

Pages